Ads
related to: dabrafenib- Read the Access Brochure
Learn about reimbursement support
and access for OJEMDA
- Contact a Rep
Learn why OJEMDA might be right
for your pediatric patients
- See Instructions for Use
Help your patients get started
with OJEMDA. Read this guidance.
- Sign Up for Updates
Sign up to stay informed
about the latest data
- Read the Access Brochure
goodrx.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Dabrafenib, sold under the brand name Tafinlar among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version of the gene BRAF. [2] Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth .
When taken in combination with dabrafenib the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash. [5] In May 2013, trametinib was approved as a single-agent by the US Food and Drug Administration for the treatment of people with V600E mutated metastatic melanoma.
B-Raf is a 766-amino acid, regulated signal transduction serine/threonine-specific protein kinase.Broadly speaking, it is composed of three conserved domains characteristic of the Raf kinase family: conserved region 1 (CR1), a Ras-GTP-binding [11] self-regulatory domain, conserved region 2 (CR2), a serine-rich hinge region, and conserved region 3 (CR3), a catalytic protein kinase domain that ...
In humans, however, ivermectin has been found to be effective when used with a melanoma chemotherapy drug called dabrafenib. Ivermectin was also found to significantly reduce lung metastasis from ...
Dabrafenib: Dostarlimab: Eflornithine: Elranatamab: To treat relapsed or refractory multiple myeloma after at least four lines of therapy [4] Enfortumab vedotin: Iptacopan: To treat paroxysmal nocturnal hemoglobinuria [4] Ivosidenib: Lecanemab: To treat Alzheimer's disease [4] Miglustat: Nedosiran
U0126 [1] [2] is the 'code' name for a compound associated with cancer treatment [3] and also in preventing ischemia and cellular oxidative stress. It also has likely utility in strokes and heart attacks. [4]
Encorafenib is indicated in combination with binimetinib, for the treatment of people with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test; [2] in combination with cetuximab, for the treatment of adults with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy; [2] in ...
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Ads
related to: dabrafenibgoodrx.com has been visited by 100K+ users in the past month